Medical Disclaimer: Do not use the information on this web site for diagnosing or treating a health problem or disease, or prescribing medication or other treatment
The impact of GLP-1 receptor agonists (GLP-1 RAs) on mental health: A systematic review
[Diabetes] runs in my family, and Id seen what my father had gone through
N Engl J Med 383(15):14131424 Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B (2021) SOLOIST-WHF Trial Investigators
EXECUTIVE SUMMARY This brief examines the financialized business model of Novo Nordisk and Eli Lilly for the leading GLP-1 products Ozempic, Rybelsus, and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide)